{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:28:16Z","timestamp":1778376496080,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Interdiscip Sci Comput Life Sci"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12539-019-00337-8","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T07:03:09Z","timestamp":1560236589000},"page":"287-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"Xinyong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingying","family":"Nong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shucai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886311207040289","volume":"11","author":"A Sgambato","year":"2016","unstructured":"Sgambato A, Casaluce F, Sacco PC et al (2016) Anti PD-1 and PD-L1 immunotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 11:62\u201368","journal-title":"Curr Drug Saf"},{"key":"337_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med 373:123\u2013135. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med 373:1627\u20131639. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"21","key":"337_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N Engl J Med 372(21):2018\u20132028","journal-title":"N Engl J Med"},{"issue":"10027","key":"337_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"S Herbst Roy","year":"2015","unstructured":"Herbst Roy S, Paul Baas, Dong-Wan Kim et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387(10027):1540\u20131550","journal-title":"The Lancet"},{"issue":"10066","key":"337_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265","journal-title":"Lancet"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"issue":"9","key":"337_CR8","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447\u2013e458","journal-title":"Lancet Oncol"},{"key":"337_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA et al (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21:371\u2013381","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"337_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"337_CR11","unstructured":"Common terminology criteria for adverse events (CTCAE). Version 4.03. \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 16 Jun 2016"},{"issue":"10","key":"337_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS et al (2016) American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343\u20131421","journal-title":"Thyroid"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1210\/jc.2014-4560","volume":"100","author":"S Orlov","year":"2015","unstructured":"Orlov S, Salari F, Kashat L et al (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100:1738\u20131741","journal-title":"J Clin Endocrinol Metab"},{"key":"337_CR14","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S et al (2018) Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109:3583\u20133590","journal-title":"Cancer Sci"},{"key":"337_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559\u2013574","journal-title":"Ann Oncol"},{"key":"337_CR16","unstructured":"Merck. Pembrolizumab US full prescribing information (2014). \n                    https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\n                    \n                  . [Accessed April 2017]"},{"key":"337_CR17","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391","journal-title":"Ann Oncol"},{"key":"337_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"key":"337_CR19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor. Rev Endocr Metab Disord therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"337_CR20","unstructured":"National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. (Version 1.2019). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf\n                    \n                  . [Accessed 14 November 2018]"}],"container-title":["Interdisciplinary Sciences: Computational Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-019-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12539-019-00337-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-019-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:24:17Z","timestamp":1591745057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12539-019-00337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s12539-019-00337-8","relation":{},"ISSN":["1913-2751","1867-1462"],"issn-type":[{"value":"1913-2751","type":"print"},{"value":"1867-1462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"24 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declared that they have no conflicts of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}